Calidi Biotherapeutics, Inc. Increase (Decrease) in Accounts Payable
Calidi Biotherapeutics, Inc. (CLDI) reported Increase (Decrease) in Accounts Payable of $306.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $74.00K, a 289.47% increase year-over-year.
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $232.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$404.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$191.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.33M.
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$628.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$6.17M, a 479.93% decline from fiscal 2022.
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.62M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $306.00K 10-Q · filed 2026-08-13 | -$98.00K derived: sum of 3 quarters · filed 2026-08-13 | -$289.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $232.00K 10-Q · filed 2026-05-14 | -$172.00K derived: sum of 2 quarters · filed 2026-05-14 | -$363.00K derived: sum of 3 quarters · filed 2026-05-14 | -$344.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$595.00K derived: sum of 2 quarters · filed 2026-03-27 | -$576.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.33M 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$172.00K derived: sum of 2 quarters · filed 2026-08-13 | -$924.00K 10-Q · filed 2025-11-13 | -$2.09M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$733.00K 10-Q · filed 2026-08-13 | -$1.90M derived: sum of 3 quarters · filed 2026-08-13 | -$2.50M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$752.00K 10-Q · filed 2026-05-14 | -$1.92M derived: sum of 2 quarters · filed 2026-05-14 | -$2.52M derived: sum of 3 quarters · filed 2026-05-14 | -$2.35M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$1.77M derived: sum of 2 quarters · filed 2026-03-27 | -$1.60M derived: sum of 3 quarters · filed 2026-03-27 | -$628.00K 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | -$605.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$431.00K derived: sum of 2 quarters · filed 2025-11-13 | $537.00K 10-Q · filed 2025-11-13 | $2.02M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.14M 10-Q · filed 2025-08-08 | $2.63M derived: sum of 3 quarters · filed 2025-08-08 | -$3.36M derived: sum of 4 quarters · filed 2025-08-08 | ||||
| 2024-03-31 | $968.00K 10-Q · filed 2025-05-14 | $2.45M derived: sum of 2 quarters · filed 2025-05-14 | -$3.53M derived: sum of 3 quarters · filed 2025-05-14 | -$5.22M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$4.50M derived: sum of 2 quarters · filed 2025-03-31 | -$6.19M derived: sum of 3 quarters · filed 2025-03-31 | -$6.17M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$5.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$7.68M derived: sum of 2 quarters · filed 2024-11-12 | -$7.66M 10-Q · filed 2024-11-12 | -$7.59M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.67M 10-Q · filed 2024-08-13 | $436.25K 10-Q · filed 2023-08-21 | -$1.61M derived: sum of 3 quarters · filed 2024-08-13 | -$46.70K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $21.00K 10-Q · filed 2024-05-14 | $90.94K 10-Q · filed 2023-05-15 | $83.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.65M derived: sum of 3 quarters · filed 2024-05-14 | $1.65M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $1.63M derived: sum of 2 quarters · filed 2024-03-15 | $1.63M derived: sum of 3 quarters · filed 2024-03-15 | $1.62M 10-K · filed 2024-03-15 | -$12.77K 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.56M derived: sum of 2 quarters · filed 2023-11-14 | $1.56M 10-Q · filed 2023-11-14 | $39.24K 10-Q · filed 2022-11-14 | $1.59M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $536.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$1.29K 10-Q · filed 2023-08-21 | $24.38K derived: sum of 3 quarters · filed 2023-08-21 | $62.54K derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | -$1.83K 10-Q · filed 2023-05-15 | $23.84K derived: sum of 2 quarters · filed 2023-05-15 | $62.01K derived: sum of 3 quarters · filed 2023-05-15 | $62.01K derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $25.68K derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $63.84K derived: sum of 2 quarters · filed 2023-03-31 | $63.84K 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $38.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $38.16K 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |